Furthermore, the intensity analyses of Notch3 intracellular domain (NICD3) normalized to GAPDH showed a significant increase in NICD3 in both ovarian cancer cell lines treated with recombinant COMP, compared with untreated cells as a control, indicating the specific activation of the Notch3 receptor upon COMP treatment (Fig. 4D, E). This evidence concerns the gene COMP and ovarian carcinoma.